Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions - Report - MDSpire
Advertisement
Case Report: Successful treatment of recurrent COVID-19 with intravenous immunoglobulin in a patient with rituximab-induced B-cell depletion and restoration of Fc-mediated effector functions
Clinical Report: Effective Management of Recurrent COVID-19 in a Rituximab-Treated Patient
Overview
This case study discusses a 47-year-old woman with B-cell depletion due to rituximab who experienced recurrent COVID-19 pneumonia. Treatment with intravenous immunoglobulin (IVIG) led to significant clinical improvement and restoration of immune functions.
Background
COVID-19 presents a significant health challenge, particularly for patients with compromised immune systems, such as those receiving B-cell-depleting therapies like rituximab. These patients are at increased risk for persistent infections and poor outcomes due to impaired antibody production. Understanding alternative therapeutic strategies, such as IVIG, is crucial for managing these vulnerable populations.
Data Highlights
No numerical data or trial data available in the source material.
Key Findings
The patient developed prolonged COVID-19 pneumonia three months post-rituximab treatment.
Standard antiviral therapies, including remdesivir and dexamethasone, were ineffective in managing her condition.
IVIG treatment resulted in rapid clinical improvement and complete resolution of oxygen requirement.
Serologic analyses showed undetectable SARS-CoV-2-specific IgG prior to IVIG, with significant increases post-treatment.
Fc-mediated immune functions, including ADCC and ADCP, were restored following IVIG administration.
Clinical Implications
The findings suggest that IVIG may serve as a beneficial adjunct therapy for patients with B-cell depletion experiencing persistent COVID-19. Clinicians should consider IVIG in similar cases where standard antiviral treatments fail.
Conclusion
This case highlights the potential role of IVIG in managing recurrent COVID-19 in patients with compromised humoral immunity due to B-cell depletion.
